Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: t36 who wrote (296)	7/28/1998 12:42:00 AM
From: Nemer	Read Replies (1) \| Respond to of 942

t36 ------ LOL at your message which does have a good point ........ ------->are we going down big tomorrow..rezulin getting slammed in the new!! sue dang, I read it twice, interpreted it again, then had to go pull up news on WLA ----- gggggggg Hey Sue ------ up there in Buffalo it might read right down here in Texas, I'm a lot slower and dumber and need help ----- my opinion ----- on your question ----- nope, not going down too much the new doesn't seem to have much effect lately talk to me some more sue ......... Regards ----- Nemer

To: t36 who wrote (296)	7/28/1998 10:53:00 AM
From: Henry Niman	Respond to of 942

Ruzlin is a TZD that activates a receptor, PPARgamma, that turns on genes which overcome insulin resistance. The activated receptor partners with another hormone receptor, RXRalpha. LGND's and AGN's rexinoids activate RXRalpha. Thus in animal models of type II diabetes, they have been shown to synergize with TZDs like WLA's Rezulin and SBH's Avandia (and TZDs are effective at lower concentrations which may avoid the liver problems). Some details at home.att.net LLY is supposed to begin Phase II clinical trials in the US soon using Targretin as monotherapy (and possibly combination therapy with Rezulin and other approved treatments for diabetes). LLY is also supposed to file INDs for one of LGND's second generation rexinoids (LGD1268 or LGD1324). A few days ago, AGN announced a deal with WLA to develop AGN's rexinoids (LGND gets royalties). The Rezulin problems may have helped seal the AGN/WLA deal. LGND had talked extensively with WLA last summer, but WLA did not want to give LGND up front funds. Consequently, LGND signed a $200 million deal with LLY, including $50 million up front and $75 million tied to early milestones such as starting US trials with Targretin or filing INDs for LGD1268 or LGD1324.